OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
Juan W. Valle, Harpreet Wasan, Andre Lopes, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 8, pp. 967-978
Open Access | Times Cited: 252
Juan W. Valle, Harpreet Wasan, Andre Lopes, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 8, pp. 967-978
Open Access | Times Cited: 252
Showing 1-25 of 252 citing articles:
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesús M. Bañales, José J.G. Marı́n, Ángela Lamarca, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 9, pp. 557-588
Open Access | Times Cited: 1739
Jesús M. Bañales, José J.G. Marı́n, Ángela Lamarca, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 9, pp. 557-588
Open Access | Times Cited: 1739
Biliary tract cancer
Juan W. Valle, Robin Katie Kelley, Bruno Nervi, et al.
The Lancet (2021) Vol. 397, Iss. 10272, pp. 428-444
Closed Access | Times Cited: 679
Juan W. Valle, Robin Katie Kelley, Bruno Nervi, et al.
The Lancet (2021) Vol. 397, Iss. 10272, pp. 428-444
Closed Access | Times Cited: 679
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Do‐Youn Oh, Aiwu Ruth He, Shukui Qin, et al.
NEJM Evidence (2022) Vol. 1, Iss. 8
Closed Access | Times Cited: 668
Do‐Youn Oh, Aiwu Ruth He, Shukui Qin, et al.
NEJM Evidence (2022) Vol. 1, Iss. 8
Closed Access | Times Cited: 668
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Juan W. Valle, Ivan Borbath, Shahid A. Khan, et al.
Annals of Oncology (2016) Vol. 27, pp. v28-v37
Open Access | Times Cited: 626
Juan W. Valle, Ivan Borbath, Shahid A. Khan, et al.
Annals of Oncology (2016) Vol. 27, pp. v28-v37
Open Access | Times Cited: 626
New Horizons for Precision Medicine in Biliary Tract Cancers
Juan W. Valle, Ángela Lamarca, Lipika Goyal, et al.
Cancer Discovery (2017) Vol. 7, Iss. 9, pp. 943-962
Open Access | Times Cited: 528
Juan W. Valle, Ángela Lamarca, Lipika Goyal, et al.
Cancer Discovery (2017) Vol. 7, Iss. 9, pp. 943-962
Open Access | Times Cited: 528
Systemic therapies for intrahepatic cholangiocarcinoma
Robin Kate Kelley, John Bridgewater, Gregory J. Gores, et al.
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 353-363
Open Access | Times Cited: 321
Robin Kate Kelley, John Bridgewater, Gregory J. Gores, et al.
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 353-363
Open Access | Times Cited: 321
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
Ángela Lamarca, Jorge Barriuso, Mairéad G. McNamara, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 1, pp. 170-185
Open Access | Times Cited: 300
Ángela Lamarca, Jorge Barriuso, Mairéad G. McNamara, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 1, pp. 170-185
Open Access | Times Cited: 300
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
Chigusa Morizane, Takuji Okusaka, Junki Mizusawa, et al.
Annals of Oncology (2019) Vol. 30, Iss. 12, pp. 1950-1958
Open Access | Times Cited: 260
Chigusa Morizane, Takuji Okusaka, Junki Mizusawa, et al.
Annals of Oncology (2019) Vol. 30, Iss. 12, pp. 1950-1958
Open Access | Times Cited: 260
Molecular Pathogenesis of Cholangiocarcinoma
Peter Labib, George Goodchild, Stephen P. Pereira
BMC Cancer (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 256
Peter Labib, George Goodchild, Stephen P. Pereira
BMC Cancer (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 256
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
Jonathan A. Ledermann, Andrew Embleton-Thirsk, Fharat Raja, et al.
The Lancet (2016) Vol. 387, Iss. 10023, pp. 1066-1074
Open Access | Times Cited: 230
Jonathan A. Ledermann, Andrew Embleton-Thirsk, Fharat Raja, et al.
The Lancet (2016) Vol. 387, Iss. 10023, pp. 1066-1074
Open Access | Times Cited: 230
Gallbladder cancer
Juan Carlos Roa, Patricia García, Vinay K. Kapoor, et al.
Nature Reviews Disease Primers (2022) Vol. 8, Iss. 1
Closed Access | Times Cited: 193
Juan Carlos Roa, Patricia García, Vinay K. Kapoor, et al.
Nature Reviews Disease Primers (2022) Vol. 8, Iss. 1
Closed Access | Times Cited: 193
Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials
Ángela Lamarca, Paul J. Ross, Harpreet Wasan, et al.
JNCI Journal of the National Cancer Institute (2019)
Open Access | Times Cited: 149
Ángela Lamarca, Paul J. Ross, Harpreet Wasan, et al.
JNCI Journal of the National Cancer Institute (2019)
Open Access | Times Cited: 149
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
Tanios Bekaii‐Saab, Juan W. Valle, Eric Van Cutsem, et al.
Future Oncology (2020) Vol. 16, Iss. 30, pp. 2385-2399
Open Access | Times Cited: 141
Tanios Bekaii‐Saab, Juan W. Valle, Eric Van Cutsem, et al.
Future Oncology (2020) Vol. 16, Iss. 30, pp. 2385-2399
Open Access | Times Cited: 141
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
Domenico Alvaro, Gregory J. Gores, Joël Walicki, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 1, pp. 181-208
Open Access | Times Cited: 140
Domenico Alvaro, Gregory J. Gores, Joël Walicki, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 1, pp. 181-208
Open Access | Times Cited: 140
Current and emerging therapies for advanced biliary tract cancers
Audrey E. Kam, Ashiq Masood, Rachna T. Shroff
The Lancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 11, pp. 956-969
Closed Access | Times Cited: 120
Audrey E. Kam, Ashiq Masood, Rachna T. Shroff
The Lancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 11, pp. 956-969
Closed Access | Times Cited: 120
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 91
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 91
Cisplatin in Liver Cancer Therapy
Sae Hamaya, Kyoko Oura, Asahiro Morishita, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10858-10858
Open Access | Times Cited: 43
Sae Hamaya, Kyoko Oura, Asahiro Morishita, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10858-10858
Open Access | Times Cited: 43
HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
Salvatore Galdy, Ángela Lamarca, Mairéad G. McNamara, et al.
Cancer and Metastasis Reviews (2016) Vol. 36, Iss. 1, pp. 141-157
Open Access | Times Cited: 167
Salvatore Galdy, Ángela Lamarca, Mairéad G. McNamara, et al.
Cancer and Metastasis Reviews (2016) Vol. 36, Iss. 1, pp. 141-157
Open Access | Times Cited: 167
Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells
Joshua M. Jackson, Małgorzata A. Witek, Joyce W. Kamande, et al.
Chemical Society Reviews (2017) Vol. 46, Iss. 14, pp. 4245-4280
Open Access | Times Cited: 158
Joshua M. Jackson, Małgorzata A. Witek, Joyce W. Kamande, et al.
Chemical Society Reviews (2017) Vol. 46, Iss. 14, pp. 4245-4280
Open Access | Times Cited: 158
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)
Hendrik‐Tobias Arkenau, Juan Martín-Liberal, Emiliano Calvo, et al.
The Oncologist (2018) Vol. 23, Iss. 12, pp. 1407-e136
Open Access | Times Cited: 148
Hendrik‐Tobias Arkenau, Juan Martín-Liberal, Emiliano Calvo, et al.
The Oncologist (2018) Vol. 23, Iss. 12, pp. 1407-e136
Open Access | Times Cited: 148
A phase 2 trial of regorafenib as a single agent in patients with chemotherapy‐refractory, advanced, and metastatic biliary tract adenocarcinoma
Weijing Sun, Anuj Patel, Daniel P. Normolle, et al.
Cancer (2018) Vol. 125, Iss. 6, pp. 902-909
Open Access | Times Cited: 111
Weijing Sun, Anuj Patel, Daniel P. Normolle, et al.
Cancer (2018) Vol. 125, Iss. 6, pp. 902-909
Open Access | Times Cited: 111
Pathogenesis of Cholangiocarcinoma
Pedro M. Rodrigues, Paula Olaizola, Nuno A. Paiva, et al.
Annual Review of Pathology Mechanisms of Disease (2020) Vol. 16, Iss. 1, pp. 433-463
Open Access | Times Cited: 108
Pedro M. Rodrigues, Paula Olaizola, Nuno A. Paiva, et al.
Annual Review of Pathology Mechanisms of Disease (2020) Vol. 16, Iss. 1, pp. 433-463
Open Access | Times Cited: 108
MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma
Andrea Lampis, Pietro Carotenuto, Georgios Vlachogiannis, et al.
Gastroenterology (2017) Vol. 154, Iss. 4, pp. 1066-1079.e5
Open Access | Times Cited: 106
Andrea Lampis, Pietro Carotenuto, Georgios Vlachogiannis, et al.
Gastroenterology (2017) Vol. 154, Iss. 4, pp. 1066-1079.e5
Open Access | Times Cited: 106
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study
Jean-Marc Phélip, Jérôme Desramé, Julien Edeline, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 3, pp. 262-271
Closed Access | Times Cited: 104
Jean-Marc Phélip, Jérôme Desramé, Julien Edeline, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 3, pp. 262-271
Closed Access | Times Cited: 104
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets
Dawn Q. Chong, Andrew X. Zhu
Oncotarget (2016) Vol. 7, Iss. 29, pp. 46750-46767
Open Access | Times Cited: 101
Dawn Q. Chong, Andrew X. Zhu
Oncotarget (2016) Vol. 7, Iss. 29, pp. 46750-46767
Open Access | Times Cited: 101
